Literature DB >> 12050490

Routine postoperative imaging is important after ureteroscopic stone manipulation.

Alon Z Weizer1, Brian K Auge, Ari D Silverstein, Fernando C Delvecchio, Ricardo M Brizuela, Philipp Dahm, Paul K Pietrow, Bertram R Lewis, David M Albala, Glenn M Preminger.   

Abstract

PURPOSE: Improved fiber optics and advanced intracorporeal lithotripsy devices have significantly decreased the incidence of complications during ureteroscopic procedures. Despite recent reports suggesting that radiographic imaging may not be necessary in all individuals after routine ureteroscopy silent obstruction may develop in some, ultimately resulting in renal damage. We determined the incidence of postoperative silent obstruction at our institution and assessed the need for routine functional radiographic studies after ureteroscopy.
MATERIALS AND METHODS: We retrospectively reviewed the charts of 320 patients who underwent a total of 459 ureteroscopic procedures for renal or ureteral calculi in a 3-year period. Complete followup with imaging was available for 241 patients (75%). Average patient age was 47.2 years. The variables of interest reviewed included preoperative pain, preoperative obstruction, targeted calculous site, stone-free rate, postoperative pain and postoperative obstruction. Mean followup was 5.4 months (range 2 to 43).
RESULTS: A total of 241 patients with complete followup were identified in this analysis. Preoperative pain was present in 202 patients (84%) and 168 (70%) had preoperative obstruction. Overall targeted calculous clearance was successful in 73% of the patients and an additional 15.8% had residual fragments less than 4 mm. The renal, proximal or mid and distal ureteral stone-free rate was 32.1%, 81.9% and 90.5%, while in an additional 46.4%, 6.3% and 6.7% of cases, respectively, residual fragments were less than 4 mm. Of the 241 patients 30 (12.3%) had obstruction postoperatively due to residual stone in 25 (83.3%), stricture in 3 (10%), edema of the ureteral orifice in 1 (3.3%) and a retained encrusted stent in 1 (3.3%). Postoperatively obstruction correlated with postoperative pain in 23 of the 30 patients (76.7%). Pain was present postoperatively in 30 of the 211 patients (14%) without evidence of ureteral obstruction postoperatively. However, silent obstruction developed in 7 patients (23.3%) or 2.9% of the total cohort. All 7 patients underwent secondary ureteroscopy to alleviate obstruction. A single patient ultimately received chronic hemodialysis for renal failure, 1 was lost to followup and in 5 there was documented successful resolution of the cause of obstruction.
CONCLUSIONS: Our analysis suggests that silent obstruction remains a potentially significant complication after stone management. Relying on postoperative pain to determine the necessity of postoperative imaging places patients at risk for progressive renal failure due to unrecognized obstruction. Therefore, we recommend that imaging of the collecting system should be performed by excretory urography, spiral computerized tomography or ultrasound within 3 months after routine ureteroscopic stone treatment to avoid the potential complications of unrecognized ureteral obstruction.

Entities:  

Mesh:

Year:  2002        PMID: 12050490

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  16 in total

1.  Effectiveness of ultrasonography in the postoperative follow-up of pediatric patients undergoing ureteroscopic stone manipulation.

Authors:  Berkan Resorlu; Cengiz Kara; Eylem Burcu Resorlu; Ali Unsal
Journal:  Pediatr Surg Int       Date:  2011-09-28       Impact factor: 1.827

Review 2.  Routine postoperative computed tomography scan after craniotomy: systematic review and evidence-based recommendations.

Authors:  Lukas Blumrich; João Paulo Mota Telles; Saul Almeida da Silva; Ricardo Ferrareto Iglesio; Manoel Jacobsen Teixeira; Eberval Gadelha Figueiredo
Journal:  Neurosurg Rev       Date:  2021-01-15       Impact factor: 3.042

3.  Evaluation of postoperative hydronephrosis following semirigid ureteroscopy: Incidence and predictors.

Authors:  Mehmet İlker Gökçe; Barış Esen; Başak Gülpınar; Adil Hüseynov; Mete Özkidik; Evren Süer
Journal:  Turk J Urol       Date:  2017-05-03

4.  Low dose lignocaine + butorphanol vs. low dose bupivacaine for spinal anaesthesia in day care urological surgeries: a prospective randomized control trial.

Authors:  Shahil Rameshbhai Khant; Rajeev Chaudhari; Rishikesh Arun Kore; Shirish Bhagwat; Ranjan Purushottam Jakhalekar
Journal:  Turk J Urol       Date:  2017-05-03

Review 5.  Percutaneous nephrolithotomy: complications and how to deal with them.

Authors:  Daniel A Wollin; Glenn M Preminger
Journal:  Urolithiasis       Date:  2017-11-17       Impact factor: 3.436

6.  Evaluation of risk factors and treatment options in patients with ureteral stricture disease at a single institution.

Authors:  Henry Tran; Olga Arsovska; Ryan F Paterson; Ben H Chew
Journal:  Can Urol Assoc J       Date:  2015-12-14       Impact factor: 1.862

7.  Selecting Treatment for Distal Ureteral Calculi: Shock Wave Lithotripsy versus Ureteroscopy.

Authors:  Ojas D Shah; Brian R Matlaga; Dean G Assimos
Journal:  Rev Urol       Date:  2003

8.  Canadian Urological Association guideline: Management of ureteral calculi - Abridged version.

Authors:  Jason Y Lee; Sero Andonian; Naeem Bhojani; Jennifer Bjazevic; Ben H Chew; Shubha De; Hazem Elmansy; Andrea G Lantz-Powers; Kenneth T Pace; Trevor D Schuler; Rajiv K Singal; Peter Wang; Michael Ordon
Journal:  Can Urol Assoc J       Date:  2021-12       Impact factor: 1.862

Review 9.  Pediatric stone disease.

Authors:  Stacy T Tanaka; John C Pope
Journal:  Curr Urol Rep       Date:  2009-03       Impact factor: 3.092

10.  Clinically insignificant residual fragments after flexible ureterorenoscopy: medium-term follow-up results.

Authors:  Faruk Ozgor; Abdulmuttalip Simsek; Murat Binbay; Tolga Akman; Onur Kucuktopcu; Omer Sarilar; Ahmet Yaser Muslumanoglu; Yalcin Berberoglu
Journal:  Urolithiasis       Date:  2014-08-01       Impact factor: 3.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.